Literature DB >> 11312328

During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

M Bendinelli1, M Pistello, D Del Mauro, G Cammarota, F Maggi, A Leonildi, S Giannecchini, C Bergamini, D Matteucci.   

Abstract

The broad resistance to antibody-mediated neutralization of lentiviruses recently isolated from infected hosts is a poorly understood feature which might contribute to the ability of these viruses to persist and to the failure of experimental vaccines to protect against virulent viruses. We studied the underlying molecular mechanisms by examining the evolution of a neutralization-sensitive, tissue culture-adapted strain of feline immunodeficiency virus upon reinoculation into specific-pathogen-free cats. Reversion to broad neutralization resistance was observed in seven of seven inoculated animals and, in individual hosts, started to develop between less than 4 and more than 15 months from infection. After comparison of the envelope sequences of the inoculum virus, of an additional 4 neutralization-sensitive in vitro variants, and of 14 ex vivo-derived variants (6 neutralization sensitive, 5 resistant, and 3 with intermediate phenotype), a Lys-->Asn or -->Glu change at position 481 in the V4 region of the surface glycoprotein appeared as a key player in the reversion. This conclusion was confirmed by mutagenesis of molecularly cloned virus. Analysis of viral quasispecies and biological clones showed that the intermediate phenotype was due to transient coexistence of neutralization-sensitive and -resistant variants. Since the amino acid position involved was the same in four of four recent revertants, it is suggested that the number of residues that control reversion to broad neutralization resistance in FIV might be very limited. Amino acid 481 was found to be changed only in one of three putative long-term revertants. These variants shared a Ser-->Asn change at position 557 in region V5, which probably collaborated with other mutations in long-term maintenance of neutralization resistance, as suggested by the study of mutagenized virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11312328      PMCID: PMC114211          DOI: 10.1128/JVI.75.10.4584-4593.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.

Authors:  H Ruppach; P Nara; I Raudonat; Z Elanjikal; H Rübsamen-Waigmann; U Dietrich
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.

Authors:  L Q Zhang; P MacKenzie; A Cleland; E C Holmes; A J Brown; P Simmonds
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

4.  Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.

Authors:  F Baldinotti; D Matteucci; P Mazzetti; C Giannelli; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  Feline immunodeficiency virus infection of cats as a model to test the effect of certain in vitro selection pressures on the infectivity and virulence of resultant lentivirus variants.

Authors:  J E Barlough; T W North; C L Oxford; K M Remington; S Dandekar; M N Ellis; N C Pedersen
Journal:  Antiviral Res       Date:  1993-12       Impact factor: 5.970

6.  Genotypic and phenotypic characterization of HIV-1 patients with primary infection.

Authors:  T Zhu; H Mo; N Wang; D S Nam; Y Cao; R A Koup; D D Ho
Journal:  Science       Date:  1993-08-27       Impact factor: 47.728

7.  Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.

Authors:  M Thali; M Charles; C Furman; L Cavacini; M Posner; J Robinson; J Sodroski
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain.

Authors:  A de Ronde; J G Stam; P Boers; H Langedijk; R Meloen; W Hesselink; L C Keldermans; A van Vliet; E J Verschoor; M C Horzinek
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

9.  Structure and variations of feline immunodeficiency virus envelope glycoproteins.

Authors:  G Pancino; I Fossati; C Chappey; S Castelot; B Hurtrel; A Moraillon; D Klatzmann; P Sonigo
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

10.  Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.

Authors:  D P Burns; C Collignon; R C Desrosiers
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more
  13 in total

1.  Feline immunodeficiency virus-infected cat sera associated with the development of broad neutralization resistance in vivo drive similar reversions in vitro.

Authors:  S Giannecchini; D Matteucci; A Ferrari; M Pistello; M Bendinelli
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Evolution of two amino acid positions governing broad neutralization resistance in a strain of feline immunodeficiency virus over 7 years of persistence in cats.

Authors:  Mauro Pistello; Donatella Matteucci; Simone Giannecchini; Francesca Bonci; Olimpia Sichi; Silvano Presciuttini; Mauro Bendinelli
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

3.  Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence.

Authors:  Margaret J Hosie; Brian J Willett; Dieter Klein; Thomas H Dunsford; Celia Cannon; Masayuki Shimojima; James C Neil; Oswald Jarrett
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Authors:  Mauro Pistello; Francesca Bonci; Elisa Zabogli; Francesca Conti; Giulia Freer; Fabrizio Maggi; Mario Stevenson; Mauro Bendinelli
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

5.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody.

Authors:  Brian J Willett; Martin Kraase; Nicola Logan; Elizabeth L McMonagle; Ayman Samman; Margaret J Hosie
Journal:  Retrovirology       Date:  2010-04-26       Impact factor: 4.602

7.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Characterization of a highly pathogenic molecular clone of feline immunodeficiency virus clade C.

Authors:  Sohela de Rozières; Candace K Mathiason; Matthew R Rolston; Udayan Chatterji; Edward A Hoover; John H Elder
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus.

Authors:  Simone Giannecchini; Mauro Pistello; Patrizia Isola; Donatella Matteucci; Paola Mazzetti; Giulia Freer; Mauro Bendinelli
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

10.  Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site.

Authors:  Carolina Herrera; Catherine Spenlehauer; Michael S Fung; Dennis R Burton; Simon Beddows; John P Moore
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.